Edolac

Quick links to important sections

Edolac

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Edolac

What is Edolac? - Overview and Quick Facts

Edolac is a prescription medicine belonging to the Nonsteroidal Anti-inflammatory Drug (NSAID) class, primarily used for its actions against pain, swelling, and stiffness. It is a synthetic, single-component drug that modulates the body's inflammatory response.

Property Description
Active ingredient Etodolac
Form Oral tablets and capsules (including extended-release)
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use (General) Relief of pain, swelling, and stiffness
Origin Synthetic (acetic acid derivative)

What Type of Medicine is Edolac? (Definition and Classification)

Edolac is a prescription-only product containing the active ingredient Etodolac, a synthetic compound that is fundamentally classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Etodolac is chemically grouped as an acetic acid derivative, distinguishing it from other common NSAIDs.

Pharmacological differentiation arises because Etodolac is a COX-2 preferential inhibitor, a characteristic clinically recognized for targeting the enzyme most active in the inflammatory process.

Composition and Available Forms of Etodolac

The medicine is a single-product composition, with its therapeutic effects derived exclusively from the synthetic compound Etodolac. The drug is consistently formulated for the oral route of administration and is supplied primarily as conventional tablets or capsules. A key distinguishing feature is the availability of extended-release tablets, a specialized form designed to ensure a consistent level of Etodolac is maintained in the body over a longer duration, optimizing relief for chronic discomfort compared to immediate-release forms.

General Purpose and Mechanism Summary

The general purpose of Edolac is to provide comprehensive symptomatic relief, often used when discomfort is accompanied by joint or muscle stiffness. Its core action is to restrict the synthesis of prostaglandins, which are chemical mediators responsible for transmitting pain signals and driving the inflammatory response. Research confirming Etodolac as an effective analgesic supports its use for managing acute and chronic pain states, helping individuals regain comfort and mobility.

Regulatory References

  1. Etodolac - LiverTox - NIH

What side effects are possible with Edolac?

Serious Warnings and Safety Information

Edolac carries an FDA Black Box Warning regarding the risk of serious, potentially fatal, cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and stroke. The risk may be higher with longer duration of use or in patients with pre-existing heart disease. The drug is contraindicated for the treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

There is also a Black Box Warning for serious, potentially fatal, gastrointestinal (GI) adverse events, including bleeding, ulceration, and perforation of the stomach or intestines. These events can occur at any time during treatment and without warning symptoms. Older adult patients (65 years and older) are at a greater risk for serious GI events.


Potential Adverse Reactions

Common (1% to 10%) side effects include dizziness, headache, edema (swelling), tinnitus (ringing in the ears), and fatigue.

Serious or Clinically Significant Adverse Reactions documented in regulatory sources also include:

  • Severe skin reactions, such as Exfoliative Dermatitis, Stevens-Johnson Syndrome (SJS), and Toxic Epidermal Necrolysis (TEN), which can be fatal.
  • Serious liver effects, including jaundice, liver necrosis, and fatal fulminant hepatitis.
  • Renal toxicity, including acute renal failure, especially in patients with existing renal or cardiac conditions.
  • New onset or worsening of high blood pressure (hypertension).
  • Anaphylactoid reactions and angioedema (swelling).

Safety Restrictions and Monitoring

Use is contraindicated in patients with a history of asthma, hives, or other allergic-type reactions after taking aspirin or other NSAIDs. It is also contraindicated after 20 weeks of pregnancy due to risk of harm to the fetus. The lowest effective dose should be used for the shortest duration possible to minimize risks. Patients should be monitored closely for new-onset or worsening hypertension, signs of fluid retention, and symptoms of GI or CV events throughout the course of therapy.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory description of Edolac (Etodolac) overdose indicates that symptoms are often limited and generally reversible with supportive care, though massive ingestion of this Nonsteroidal Anti-inflammatory Drug (NSAID) may lead to severe outcomes.

Overdose Manifestations and Outcomes (Regulatory Basis) Required Emergency Action
Documented Manifestations: Gastrointestinal effects (nausea, vomiting, epigastric pain, GI bleeding); Central Nervous System effects (lethargy, drowsiness, headache, dizziness) [Source: FDA/NIH] Seek emergency medical help right away if an overdose is suspected [Source: NIH]
Severe Outcomes: Potential for serious events, including acute renal failure, coma (following massive ingestion), respiratory depression, hypertension, hypotension, and anaphylactoid reactions [Source: FDA/NIH] Immediately call emergency services (911/equivalent) if the person has collapsed, had a seizure, has trouble breathing, or cannot be awakened [Source: NIH]

Antidote and Management:

No specific antidote is known for Etodolac overdose. Management is generally symptomatic and supportive, utilizing procedures such as gastric lavage and administration of activated charcoal [Source: FDA]. Continuous monitoring for signs of serious complications, particularly GI bleeding and renal function impairment, is appropriate given the known risks of the NSAID class [Source: FDA]. Older adults are noted in regulatory warnings to be at higher risk for serious gastrointestinal events, which is a key consideration in any overdose scenario [Source: FDA].

Therapeutic Uses of Edolac

Edolac (Etodolac) is commonly used for managing symptoms related to physical discomfort in clinical settings marked by increased discomfort or tension stemming from inflammation. The medication is relevant for managing symptoms that often interfere with daily comfort and create noticeable physiological strain.

Core Therapeutic Focus

This domain covers the medication's use in providing sustained support against the persistent pain, swelling, and stiffness associated with long-term conditions. It is used in situations involving certain distressing symptoms across conditions such as Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Juvenile Rheumatoid Arthritis (JRA). It is also relevant for managing JRA in pediatric patients.

The medication is applied during phases of increased distress, such as following surgical procedures (postoperative discomfort) or during sudden, painful episodes like acute gouty arthritis flares. It is considered relevant for managing the cluster of pain, inflammation, and stiffness.

“Edolac supports patients during episodes of heightened discomfort and assists with maintaining functional stability.”

Quick Fact: Support for Symptoms of Joint Pain, Stiffness, and Swelling It contributes to improved comfort by addressing symptoms that become more disruptive during flare-ups and provides supportive relief when symptoms interfere with routine activities.

Regulatory References

  1. DailyMed overview from the National Library of Medicine

Eligibility and Restrictions for Use

Who can and cannot use Edolac?

Edolac (etodolac) eligibility is strictly defined by regulatory authorities based on age, pre-existing conditions, and physiological status.

Populations Permitted or Requiring Caution

Population Group Eligibility Status
Adults Generally approved for use.
Pediatric (6 to 16 years) Approved only for Juvenile Rheumatoid Arthritis (JRA); general use not established.
Older Adults (65 years) Use is permitted, but requires caution due to increased risks of gastrointestinal events and decreased renal function.

Absolute Contraindications

Edolac must not be used by the following groups:

  • Patients with a known hypersensitivity to Etodolac or any NSAID that has caused allergic reactions (e.g., asthma, urticaria).
  • Patients with severe heart failure, severe renal failure, or active/recurrent gastrointestinal bleeding or ulcers.
  • Treatment of pain after Coronary Artery Bypass Graft (CABG) surgery.
  • Pregnant women at or after 20 weeks gestation (risk to the fetus).
  • Women who are breastfeeding (use is generally not recommended).

Use is also not recommended for women who are attempting to conceive, as the medicine may impair female fertility.

What should I know about interactions with other medicines?

The official regulatory profile for Edolac (Etodolac) defines specific interaction patterns that impose restrictions on co-administration with other medicines and substances. Use is formally contraindicated for the management of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. Co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or high-dose aspirin should be avoided due to the documented potential for enhanced adverse effects.

The interaction profile features significant pharmacodynamic reinforcement, particularly with oral anticoagulants, such as Warfarin. This combination enhances the anticoagulant effect, officially increasing the risk of serious gastrointestinal bleeding. Edolac may also reduce the natriuretic effect of diuretics (e.g., Furosemide) and diminish the antihypertensive action of ACE-inhibitors and ARBs.

Interactions affecting drug exposure include those with Lithium, where Edolac is documented to reduce its renal clearance, leading to an elevation of plasma lithium levels and increased toxicity risk. The serum levels of Cyclosporine and Digoxin may also be elevated. The profile mandates a timing constraint to avoid Edolac for 8–12 days following mifepristone administration. Finally, the combination with alcohol is officially noted to increase the risk of serious gastrointestinal bleeding.

Mechanism of Action

How Edolac Works

The mechanism of action of Edolac (Etodolac) focuses on the enzyme system responsible for generating inflammatory mediators. Its primary action is the preferential inhibition of the Cyclooxygenase-2 (COX-2) enzyme. Edolac acts as a reversible, non-competitive inhibitor, binding to the enzyme's active site to suppress its catalytic function. The S-enantiomer is the pharmacologically active stereoisomer responsible for this inhibition.

This molecular interaction interrupts the arachidonic acid cascade, limiting the conversion of arachidonic acid into prostaglandin precursors. The resulting reduction in prostaglandin synthesis leads to a decrease in the concentration of these potent signaling molecules throughout the affected tissues.

At a physiological level, the mechanism results in the modulation of peripheral signaling pathways. Lowered prostaglandin levels are associated with a reduction in the sensitization threshold of nociceptors (pain-sensing nerves) and contribute to the regulation of localized fluid dynamics and thermal responses, thereby altering the overall physiological reaction to cellular irritation.

Dosage and Administration Information

How Edolac is Used: Official Administration Guidelines

Edolac (Etodolac) is administered strictly by the oral route, utilizing either immediate-release (IR) capsules/tablets or extended-release (ER) tablets. The official instructions emphasize using the lowest effective dose for the shortest duration consistent with the patient’s treatment goal.


Standard Dosing and Frequency

Dosage depends on the formulation used and whether the drug is prescribed for short-term or chronic use, as outlined in official prescribing information.

Usage Type Form Typical Daily Dose Range Maximum Daily Dose Frequency
Acute Pain (Adult) Immediate-Release 200–400 mg per dose 1000 mg Every 6 to 8 hours
Chronic Conditions (Adult) Immediate-Release 600–1000 mg 1000 mg In divided doses (2-3 times/day)
Chronic Conditions (Adult) Extended-Release 400–1000 mg 1200 mg Once daily (QD)

Administration Requirements

  • Food Intake: Edolac may be taken with or without food. While food can affect the rate of absorption for the IR form, the extent of absorption is not substantially changed.
  • Extended-Release Handling: ER tablets must be swallowed whole. They must not be crushed, broken, or chewed to maintain their controlled-release mechanism.
  • Duration: For chronic conditions, the dose should be reviewed and adjusted to the lowest amount that maintains the response once achieved.

Population-Specific Use

  • Pediatric Patients: Use is established only for Juvenile Rheumatoid Arthritis (JRA) with the Extended-Release formulation. Dosing is strictly weight-based, ranging from 400 mg to 1000 mg once daily for children weighing 20 to over 60 kg.
  • Older Adults (≥65 years): No general dose adjustment is required based on pharmacokinetics, but the lowest possible dose and shortest duration of use are recommended due to increased sensitivity.

Recent Clinical Evidence

Research evidence / Overview of studies for Edolac (Etodolac)

Evidence Supporting Use in Osteoarthritis (OA) and Rheumatoid Arthritis (RA)

The evidence for the use of Edolac is derived primarily from Randomized Controlled Trials (RCTs) and systematic reviews, where the drug was evaluated in adult patients with conditions characterized by functional limitations and cycles of stability and flare-ups. Studies reported measurements of how symptoms evolved, with research describing the specific outcomes related to pain scores and physician-assessed functional mobility across the study duration.

Patient-reported outcomes describing perceived discomfort were documented in trial reports over the short-term follow-up periods. Controlled data characterizing the long-term outcomes and the consistency of measured symptomatic change beyond the typical follow-up periods of the primary RCTs (which were often limited to several weeks or a few months) are not well characterized. Additionally, the research has not explored outcomes related to disease progression or structural changes in the joint itself.


Studies on Acute Pain and Inflammatory Flares

The evidence base largely consists of single-dose and short-term RCTs that examined the time until the start of the effect and the symptom measurements over several hours following administration. These studies were relevant in trials assessing short-term or episodic symptom patterns in conditions associated with acute or disruptive episodes.

Findings describe patterns observed related to objective measurements of perceived discomfort, documenting a measurable alteration in pain scores across the short observation periods. Because the research explores temporary physiological imbalance, the follow-up durations were naturally limited. This provides limited insight into the management of complex or chronic pain states that extend over weeks or months.


What Remains Uncertain in the Research Landscape

The existing research provides context but not individual predictions for personal outcomes. A key limitation is that follow-up durations were limited in many of the core RCTs relative to the chronic nature of conditions like Osteoarthritis and Rheumatoid Arthritis. Furthermore, the research primarily focuses on outcomes related to physical discomfort and symptomatic change; data on disease modification or the rate of structural progression are not typically evaluated within the core drug evidence base. Comparative evidence against the full range of modern non-NSAID therapies is not universally available, and data for certain groups remain insufficient.

Key Studies & References

  1. Etodolac (DailyMed Monograph)

Frequently Asked Questions (FAQ)

Common questions about Edolac (FAQ)

Q: Does Edolac help with pain right away or does it take time to work?

Studies described in the official documents show that pain relief effects can be observed as early as 30 minutes after taking the medicine. The maximum pain-relieving effect typically occurs within one to two hours following administration.

Q: Is there a list of ingredients in Edolac I should be aware of?

Yes, regulatory documents list both the active ingredient, Etodolac, and all inactive ingredients used in the formulation. These ingredients may include common excipients like lactose monohydrate, iron oxides, and various color additives. This comprehensive list is included in the official product information for reference.

Q: Is Edolac considered a long-term treatment or is it usually short-term?

According to official regulatory documents, Edolac is approved for both short-term use in managing acute pain and for the longer-term management of chronic conditions. These chronic conditions include the symptoms associated with osteoarthritis and rheumatoid arthritis.

Q: Is Edolac known to cause drowsiness or affect driving ability?

Official product information reports side effects such as dizziness and drowsiness. Official warnings state that because these effects may occur, caution should be exercised when performing activities that require alertness, such as driving or operating heavy machinery.

Q: Can Edolac be used by people who have mild kidney problems?

Use is strictly prohibited (contraindicated) in people with severe kidney failure. For patients who have existing or less severe kidney issues, the drug information states that caution should be exercised due to the documented potential for renal toxicity.

Q: What is the risk of having an allergic reaction to Edolac?

Official safety documents describe the possibility of serious, allergic-type reactions, such as anaphylactoid reactions and angioedema (swelling). These reactions are rare but can be life-threatening. Regulatory sources typically describe the severity and type of these events but do not provide a statistical frequency or percentage risk.

Q: Are there known food items or beverages to avoid while taking Edolac?

Official warnings highlight that combining Edolac with alcohol increases the documented risk of serious gastrointestinal bleeding. The official administration guidelines indicate that the medicine can otherwise be taken with or without food.

Q: Is it normal to feel a bit nauseous when starting Edolac?

Yes, according to official adverse reaction data, nausea is a commonly reported symptom. It is listed as occurring in between 3% to 9% of patients in clinical trials. This falls within the range of expected side effects.

Q: What conditions are listed as the primary indications for Edolac?

Official regulatory labeling states that Edolac is indicated for the management of acute pain. It is also approved for the relief of symptoms related to chronic inflammatory joint conditions, specifically osteoarthritis, rheumatoid arthritis, and certain types of juvenile arthritis.

Q: Are there any documented long-term benefits to using Edolac?

The research evidence found in official documents focuses primarily on short-term follow-up periods. These documents note that data characterizing the consistency of symptomatic change or long-term outcomes beyond these initial periods are not well characterized.

Q: How long does the effect of one dose of Edolac typically last?

According to clinical trial information, the pain-relieving effect of a single dose of Edolac typically lasted for a period of four to six hours. This duration can vary based on the dosage form used and individual patient response.

Q: What does the term 'contraindication' mean in relation to Edolac?

In the context of official drug labeling, a contraindication describes a health condition or physiological state that makes the use of the medicine unsafe and improper. For Edolac, regulatory documents list specific contraindications, such as severe heart failure, active gastrointestinal bleeding, and use after 20 weeks of pregnancy.

Q: If I miss a dose of Edolac, what is the generally accepted advice?

The official patient information typically describes a protocol to address missed doses. This protocol involves taking the missed dose if remembered soon after, but instructs patients to skip it and resume the normal schedule if the next dose time is near. This standard guidance aims to prevent taking a double dose.

Q: Is Edolac a narcotic or a controlled substance?

Edolac is chemically classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). It is not currently listed as a narcotic or a controlled substance by regulatory bodies like the U.S. Drug Enforcement Administration (DEA).

Q: Is Edolac known to cause changes in mood or anxiety?

Yes, official regulatory documents list both depression and anxiety among the reported adverse reactions associated with the medicine. These are noted as changes related to the nervous system.

Q: Does Edolac interact with any herbal teas or remedies?

Official interaction warnings are primarily focused on prescription drugs and alcohol. However, regulatory guidance emphasizes that all substances being taken, including any herbal teas, remedies, or supplements, should be reviewed by a prescriber to minimize the risk of unknown interactions.

Q: What are the official recommendations regarding caffeine intake with Edolac?

Official regulatory labels do not specify a known drug-to-drug interaction between Etodolac and caffeine. Nevertheless, general patient guidance has been noted to reference the possible benefit of limiting consumption of irritants like coffee or other caffeinated beverages to help reduce the potential risk of stomach irritation.

How should Edolac be stored and disposed of?

Official Storage Requirements

Edolac (etodolac) must be stored at Controlled Room Temperature, which is officially defined as 20 C to 25 C (68 F to 77 F), with permitted brief excursions between 15 C and 30 C (59 F and 86 F). The medicine requires protection from adverse conditions, meaning it must be protected from moisture and kept from freezing or excessive heat.

Packaging and Child Safety

For stability, the medication must be stored in a well-closed container and the container must be kept tightly closed to maintain its protective environment. All forms of Edolac must be stored out of the reach of children.

Disposal Instructions

Expired or unused Edolac should be disposed of using a drug take-back program whenever available. If no take-back program is accessible, the medicine should be disposed of in household trash after being mixed with an unappealing substance, such as dirt or used coffee grounds, and placed in a sealed bag. Edolac is not on the FDA flush list and should not be flushed down a toilet or drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Edolac found in:

A-Z Index: